Merck acquires Idenix
Mylan buys Agila
Cipla invests in SA pharma space
ThermoFisher acquires Life Tech
Eli Lilly invests $70 mn in China
Global pharmaceutical company, Merck, decides to acquire Idenix Pharmaceuticals, engaged in drug discovery for human viral diseases, at $3.85 billion.
Already having three drug candidates for hepatitis C virus (HCV) infection in clinical development- two nucleotide prodrugs (IDX21437 and IDX21459) and a NS5A inhibitor (samatasvir), Idenix's primary focus is on the development of next-generation oral antiviral therapeutics.
Mylan invested $1.75 billion to buy generic injectable maker, Agila Specialities, from Indian drug maker Strides Arcolab.
The acquisition is intended to expand Mylan's product portfolio with around 300 filings approved globally and marketed in around 70 countries.
Agila's acquisition complement Mylan's existing injectables platform of more than 500 products marketed globally and sterile manufacturing facilities in Ireland and India.
In a major acquisition deal, India based Cipla invested $512 million to acquire Cipla Medpro, its distribution partner in South Africa and third-largest pharma company in the country.
Expanding presence in South Africa market, Cipla intends to grow further in the region
Global pharma company, Eli Lilly, expanded its manufacturing and development presence in China by investing around $70 million in a manufacturing facility to develop Lilly-branded generic drugs.
The plant is designed to employ 350 headcount with a production capacity of 2.2 billion units.